Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical
“Infusion sets provide people flexible options in insulin pump wearability, and we are dedicated to expanding our portfolio of sets to offer our customers even greater choice in personalizing their therapy management system,” said
Capillary Biomedical’s unique extended wear infusion set technology is currently in development and not commercially available. Financial terms were not disclosed.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the Company’s future development of new diabetes-related products and services, the Company’s advancement of infusion set offerings, including its continued development and introduction of an extended wear infusion set, the ability of the Company to successfully obtain FDA approval for its infusion set, and the timing of the launch of the infusion set. These statements are subject to numerous risks and uncertainties, including the Company’s ability to innovate and manage growth, the Company’s ability to successfully integrate Capillary Biomedical’s infusion set products and designs into the Company’s diabetes-related products and services, the Company’s ability to successfully manufacture and launch the Capillary Biomedical infusion set, and uncertainties regarding market conditions impacting the Company’s business and industry, as well as other risks identified in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and other documents that we file with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005859/en/